Elevated thrombotic activity after myocardial infarction: A 2-year follow-up study

Haemostasis

Volumn 28, Issue 6, 1998, Pages 301-306

  Martinez Sales V ^a   Vila, V ^a   Reganon E ^a   Goberna, M A ^a   Ferrando, F ^a   Palencia, M A ^a   Aznar, J ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Fibrinogen; Fibrinopeptide A.; Myocardial infarction; Prothrombin fragment 1+2; Tissue factor; Tissue factor pathway inhibitor; Von Willebrand factor; Thromboglobulin

Indexed keywords

ACETYLSALICYLIC ACID; BETA THROMBOGLOBULIN; FIBRINOGEN; FIBRINOPEPTIDE A; PROTHROMBIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HEART INFARCTION; HUMAN; IMMUNOBLOTTING; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; THROMBOSIS;

EID: 0032322847     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000022446     Document Type: Article

References (23)

1. Vila V, Réganon E, Aznar J, Lacueva V, Ruano M, Laiz B: Hypercoagulable state after thrombolytic therapy in patients with acute myocardial infarction (AMI) treated with streptokinase. Thromb Res 1990;57:783-794.
2. Réganon E, Vila V, Aznar J, Lacueva V, Martinez V, Ruano M: Studies on the functionality of newly synthesized fibrinogen after treatment of acute myocardial infarction with streptokinase. Increase in the rate of fibrinopeptide release. Thromb Haemost 1993;70:978-983.
3. Galvani M, Abendschein DR, Ferrini D, Ottani F, Rusticali F, Eisenberg PR: Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase. J Am Coll Cardiol 1994;24:1445-1452.
4. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Spinola A, Cattaneo M, Broccolino M, Mannucci M, Rosenberg RD: Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol 1995;25:203-209.
5. Salvioni A, Marenzi G, Lauri G, Giraldi F, Perego GB, Grazi S, Guazzi MD: β-Thromboglobulin plasma levels in the first week after myocardial infarction: Influence of thrombolytic therapy. Am Heart J 1994;128:472-476.
6. Andreotti F, Roncaglioni MC, Hackett DR, Khan MI, Regan T, Haider AW, Davies GJ, Kluft C, Maseri A: Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 von Willebrand factor in acute myocardial infarction. J Am Coll Cardiol 1990;16:1553-1560.
7. Magulis T, Davis M, Maor N, Soff GA, Grenadier E, Palant A, Aghai E: The von Willebrand factor in myocardial infarction and unstable angina: A kinetic study. Thromb Haemost 1986;55:366-368.
8. Lorena M, Perolini S, Casazza S, Milani M, Cimminiello C: Fluvastatin and tissue factor pathway inhibitor in type IIA and IIB hyperlipidemia and in acute myocardial infarction. Thromb Res 1997;87:397-403.
9. Suefuji H, Ogawa H, Yasue H, Kaikita K, Souejima H, Motoyama T, Mizuno Y, et al: Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J 1997;134:253-259.
10. Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, Prisco D, Pepe G, Abbate R, Gensini GF, Neri Serneri GG: Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost 1998;79:495-499.
11. Granger ChB, Becker R, Tracy RP, Califf RM, Topol EJ, Pieper KS, Ross AM, et al: Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: Results from the GUSTO-I trial. J Am Coll Cardiol 1998;31:497-505.
12. Low EJ, Hill HB, Searly RL: Simple method for determination of normal plasma fibrinogen levels. Am J Clin Pathol 1967;47:538-548.
13. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T. Nature 1970;227:680-686.
14. Towbin H, Stachelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitro-cellulose sheets. Procedure and some applications. Proc Natl Acad Sci USA 1979;76:4350-4354.
15. Kockum C, Frebelius S: Rapid radioimmunoassay of human fibrinopeptide A - Removal of cross-reacting fibrinogen with bentonite. Thromb Res 1980;19:589-598.
16. Rapold HJ, de Bono D, Arnold AER, Arnout J, De Cock F, Coller D, Vestratete M, for the European Cooperative Study Group: Plasma fibrinopeptide A levels in patients with acute myocardial infraction treated with alteplase: Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. Circulation 1992;85:928-934.
17. Merlini PA, Bauer KA, Oltrona L, Ardissini D, Cattaneo M, Belli C, Mannucci PM, Rosemberg RD: Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994;90:61-68.
18. Becker RC, Cannon CP, Bovill EG, Tracy RP, Thompson B, Knatterud GL, Randall A, et al: Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB trial). Am J Cardiol 1996;78:142-147.
19. Bauer KA, Rosemberg RD: The patophysiology of the prethrombotic state in humans: Insight gained from studies using markers of hemostatic system activation. Blood 1987;70:343-350.
20. Stel HV, Sakariassen KS, De Groot PG, van Mourik JA, Sixama JJ: von Willebrand factor in the vessel wall mediates platelet adherence. Blood 1985;65:85-90.
21. Tousoulis D, Davies G, Tentolouris C, Bosinakou E, Toutouzas P: Relation of von Willebrand factor to occurrence of Q waves and thrombolytic treatment in acute myocardial infarction. Am J Cardiol 1998;81:497-500.
22. Uren NG, Crake T, Lefroy DC, De-Silva R, Davis GJ, Maseri A: Reduced coronary vasodilatator function in infarcted and normal myocardium after myocardial infarction. N Engl J Med 1997;331:222-227.
23. Davis MJ: A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation 1990;82(suppl II):II-38-II-46.